Kornimate/medical-research-clean huggingface dataset:
study of brain circuitry in anxiety disorders

Conditions: Posttraumatic Stress Disorder; Panic Disorder; Specific Phobias

Summary: a diverse body of research has implicated the amygdalo-cortical circuitry in the pathophysiology of anxiety disorders. for example, one model of ptsd posits exaggerated amygdala responsivity to threat-related stimuli as well as deficient top-down modulation of amygdala responses by specific cortical regions, including the pregenual anterior cingulate cortex, subcallosal cortex, and hippocampus. the investigators propose to investigate the pathophysiology of several specific anxiety disorders, posttraumatic stress disorder (ptsd), panic disorder (pd), and specific phobia(sp), by using cognitive activation paradigms and magnetic resonance imaging (mri) to probe the function and structure of implicated amygdalo-cortical circuitry.

all candidates for this project will undergo a comprehensive clinical assessment by an investigator trained to administer these instruments. at the mgh fmri center in charlestown or at the neuroimaging center at mclean hospital in belmont, ma; each subject will undergo a single mri session lasting approximately 2 hours. after the scanning session, subjects may be asked to make judgments about the facial expressions or the words that were presented.

Eligibility criteria:
inclusion criteria: * 18 - 65 years of age * right-handed (edinburgh inventory - oldfield 1971) * scid diagnosis consistent with group designation: current ptsd (ptsd group; none current or past (nc and tenc group); current sp (must be to small animal phobia, sp group); current pd (pd group) * to be matched for age, gender, and years of education, as well as self-identified race/ethnicity. * for female subjects, stage of menstrual cycle will be ascertained by history (see appendix), and dates of fmri acquisition will be scheduled to prevent systematic differences between groups with respect to this variable. exclusion criteria: * neurologic or medical condition that would interfere with study procedures or confound results, ascertained by history. * history of seizure or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion) * history of exclusionary axis i psychiatric diagnosis (other than as specified); i.e., history of substance use disorder, psychotic disorder, bipolar disorder, tic disorder, or eating disorder. note that comorbid current major depressive disorder will be allowed in up to one half of each study group. this will enable inclusion of this common comorbidity, but also enable a definitive assessment of whether or not the presence of this comorbid diagnosis is driving any observed significant between group differences. * use of psychotropic medication within 4 weeks prior to study (within 6 weeks for fluoxetine, or other long-lived compounds; within one year for neuroleptics). * pregnancy (to be ruled out by urine ß-hcg). * metallic implants or devices contraindicating magnetic resonance imaging.
randomized, controlled, double-blind study of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis.

Conditions: Candidiasis, Esophageal; HIV Infections

Summary: to evaluate the safety and efficacy of itraconazole oral solution versus fluconazole tablets for the treatment of esophageal candidiasis in immunocompromised patients.


Eligibility criteria:
inclusion criteria patients must have: * esophageal candidiasis. * histological evidence of candida spp. at baseline with confirmation by positive mycological culture. * hiv infection or other predisposing risk factor. * life expectancy of at least 2 months. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * malignancies of the head or neck, if the treatment or disease will interfere with response assessment. * evidence of systemic fungal infection. * underlying clinical condition that would preclude study completion. * judged to be unreliable in regard to following physician's directives. concurrent medication: excluded: * rifampin. * rifabutin. * phenobarbital. * phenytoin. * carbamazepine. * terfenadine. * astemizole. * h2 blockers. * continual antacids. * any investigational drug (expanded access drugs are allowed). patients with the following prior conditions are excluded: * history of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry. * history of hypersensitivity to imidazole or azole compounds. prior medication: excluded: * other orally administered antifungal therapy within 3 days prior to study entry. * any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).

Keywords: itraconazole fluconazole acquired immunodeficiency syndrome candidiasis immunocompromised host
kidney function and risk factors in patients with metastatic castration-resistant prostate cancer (mcrpc) undergoing 177lutetium-psma radioligand therapy: a prospective observational study - kiri-trial

Conditions: Kidney Disease; Radiation Nephropathy; Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Summary: the goal of this observational study is to determine the impact of 177lutetium-prostate specific membrane antigen (psma) radioligand therapy (177lu-psma-rlt) on kidney function over time. the main question it aims to answer is: what is the absolute decline in estimated glomerular filtration rate (egfr) in patients undergoing 177lu-psma-rlt after 12 and 24 months? patients treated with 177lu-psma-rlt will have their kidney function monitored before, during, and after therapy using routine markers like creatinine and cystatin c. additional biomarkers and urine proteomics will be collected to identify early detection markers and risk factors for chronic kidney disease (ckd). follow-up examinations will be conducted at regular intervals up to 5 years. the study also aims to correlate clinical risk factors and patient-reported outcomes with kidney insufficiency to assess the impact of therapy and identify vulnerable patient groups.

patients with mcrpc treated at klinikum rechts der isar who are newly receiving therapy with 177lu-psma-rlt will be included. to ensure data quality, standard operating procedures (sops) will be implemented for both technical measurements and data collection. data entered into the registry will undergo double data verification against predefined rules for range and consistency with other data fields. this ensures the accuracy and reliability of the collected data. a detailed data dictionary will be maintained, describing each variable used in the registry, including its source, coding information (e.g., tnm staging system), and normal ranges if relevant. patient reported outcomes (prom) of cancer related symptoms and quality of life will be collected using standardized questionnaires. based on the power calculation, a total of 100 patients will be included in the study. these patients will be followed up for a period of up to 5 years to ensure comprehensive data collection and analysis.

Eligibility criteria:
inclusion criteria: * patients with mcrpc starting 177lu-psma rlt at the klinikum rechts der isar at the time of therapy initiation (1st cycle). exclusion criteria: * missing or incomplete informed consent. * age below 18 years

Keywords: mcrpc 177lutetium 177lu-psma radioligand therapy
decision aid for dementia therapies

Conditions: Dementia; Decision Aids

Summary: the purpose of this study is to develop a decision aid to support patients and families making decisions about medications for dementia.


Eligibility criteria:
inclusion criteria: patients: * uchealth patient * ages 18 y/o and above * documented neurocognitive deficits suggestive of mild cognitive impairment or early dementia as determined by their treating clinician. * english or spanish speaking caregiver: * ages 18 y/o and above * identified by the study participant as the person who helps the most with their medical care outside the hospital or clinic. * english or spanish speaking clinicians: * neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making. * english or spanish speaking exclusion criteria: patients: * not english or spanish-speaking * neurocognitive deficits suggestive of moderate or severe cognitive impairment or late stage dementia. * not able to consent for themselves caregiver: * ages 17 y/o and below * not english or spanish-speaking clinicians: * neurologists, primary care clinicians, pharmacists, or psychologists involved in dementia decision-making. * english or spanish-speaking

Keywords: lecanemab
quadratus lumborum block for congenital hip dislocation surgery

Conditions: Congenital Hip Dislocation

Summary: developmental dysplasia of the hip (ddh) is one of the major disorder of the pediatric population with an incidence of 3 to 5 per 1000 children. open surgical reduction of congenital hip dislocation (chd) is typically performed after an ineffective closed reduction or older than 18 months. multiple femoral or pelvic osteotomies and tenotomies are performed during this surgical treatment and cause severe postoperative pain.since initial description for abdominal surgery, the quadratus lumborum block has experienced several surgeries for postoperative pain management in adults and pediatrics. one of these indication is the hip surgery and described for adult hip arthroplasty. in addition we reported two pediatric cases that single dose transmuscular quadratus lumborum block is an affective analgesia for chd surgery. the aim of this study was to evaluate the analgesic effect of ultrasound guided transmuscular quadratus lumborum block in pediatric patients undergoing chd surgery.


Eligibility criteria:
inclusion criteria: - american society of anesthesiologist's physiologic state i-ii patients undergoing hip dislocation surgery exclusion criteria: * chronic pain * bleeding disorders * renal or hepatic insufficiency * patients on chronic non-steroidal anti-inflammatory medications * emergency cases * incomplete patient forms * infection of the skin at the site of needle puncture area * patients with known allergies to any of the study drugs * american society of anesthesiologist's iii-iv
bacterial infections in patients with cirrhosis in argentina: clinical and microbiological characteristics

Conditions: Bacterial Infections; Cirrhosis; Resistant Infection; Morality

Summary: in recent years, there has been an increasing prevalence of bacterial infections caused by multiresistant and extremely resistant organisms in patients with cirrhosis. these infections are associated with a worse prognosis, generate difficulties in the management of the patient during hospitalization and increase health costs. the main objective of this project is to estimate the prevalence of infections by multiresistant bacteria in patients with cirrhosis. additionally, the prevalence of other antibiotic resistance patterns and morbi-mortality in the study population will be evaluated. for these purposes, a multicenter prospective cohort study will be carried out, including patients with cirrhosis who present bacterial infections at the time of admission, or during hospitalization. performing a study in argentina on the clinical and microbiological characteristics of bacterial infections in patients with cirrhosis could be very useful to develop new strategies for prevention and treatment of this severe complication.


Eligibility criteria:
inclusion criteria: * patients with cirrhosis * patients older than 17 years. * patients who are hospitalized for bacterial infections, or who develop bacterial infections while hospitalized exclusion criteria: • refusal to participate in the informed consent process
postoperative radiotherapy for oral squamous cell carcinoma after neoadjuvant therapy and surgery

Conditions: Radiotherapy; Neoadjuvant Therapy; Oral Squamous Cell Carcinoma; Surgery

Summary: the treatment guideline for locally advanced resectable oral squamous cell carcinoma (laroscc) is surgery + postoperative radiotherapy/chemoradiotherapy. though the treatment is intensive with serious harm to quality of life, the survival of patients is poor. neoadjuvant therapy has been evaluated in a number of clinical trials for laroscc, but failed to directly improve the overall survival. on the other hand, de-escalation of treatment followed by neoadjuvant is also been explored with some promising results. this study is to retrospectively include patients with laroscc who received neoadjuvant therapy and surgery. survival between patients in two cohorts (cohort 1: received postoperative radiotherapy, cohort 2: received no postoperative radiotherapy) are to be compared.


Eligibility criteria:
inclusion criteria: * patients receiving neoadjuvant therapy and surgery for oral squamous cell carcinoma from january 2008 to december 2021 * oral squamous cell carcinoma histology (including tongue, gingiva, cheek, floor of mouth, hard palate and posterior molar area) * clinical stage iii/iva (t1-2/n1-2/m0 or t3-4/cn0-2/m0, ajcc 2018) for the primary lesion * surgical resection samples that can be evaluated for pathological remission rate exclusion criteria: * severe/active systemic disease * previously radiotherapy or neck lymph node dissection for the head and neck region * evidence of tumor recurrence or metastasis in physical examination or imaging (ultrasound, ct, mri) before initiation adjuvant radiotherapy * evidence of severe/unrelieved side effects of neoadjuvant therapy or severe postoperative complications before initiation adjuvant radiotherapy
impact of pain on functional impairment and quality of life in adults with hemophilia

Conditions: Congenital Bleeding Disorder; Haemophilia A; Haemophilia A With Inhibitors; Haemophilia B; Haemophilia B With Inhibitors

Summary: this study is conducted in the united states of america (usa). the aim of the study is to assess the impact of pain on functional impairment and quality of life in adult persons with hemophilia (pwh) with and without inhibitors with joint bleeding.


Eligibility criteria:
inclusion criteria: * adult males able to provide consent and complete a survey in english * congenital hemophilia a or b with or without inhibitors with any history of joint bleeding or joint pain * presentation at the treatment center for a comprehensive annual visit where joint range of motion will be obtained * informed consent obtained before any study-related activities. (study-related activities are any procedure related to recording of data according to the protocol) exclusion criteria: * previous participation in this study
clearpetra™ vacuum-assisted ureteral access sheath vs traditional approach

Conditions: Nephrolithiasis; Kidney Stone

Summary: ureteroscopy has been considered the best approach when treating renal stones smaller than 2 cm. this procedure is usually performed together with ureteral access sheaths, which helps protect the ureter mucosa and lowers intrarenal pressure. recently, a new vacuum-assisted ureteral access sheath called clearpetra has entered us market and allows for continuous stone fragmentation and aspiration. because there is little information on comparing this device with traditional approach (no sheath or non-vacuum-assisted sheath) in american population, we aim to compare those devices in terms of their ability to clear the kidney from kidney stones, as well as reduce infection rates postoperatively.

retrograde intrarenal surgery (rirs) is now considered gold-standard for treatment of renal stones smaller than 2 cm. this procedure often employs a ureteral access sheath (uas), as it helps to reduce intrarenal pressure and protects the ureter mucosa when basketing is required. however, the challenge imposed by residual stone fragments and sepsis remains. additionally, natural elimination of residual stone fragments may induce renal colic, hematuria an even the potential for new stone development. recently, a new vacuum-assisted ureteral access sheath (va-uas) named clearpetra™ provides concomitant stone fragmentation and aspiration. the new clearpetra™ vacuum assisted ureteral access sheath allows simultaneous fragmentation and extraction of stones. it is a disposable access sheath equipped with a continuous flow aspiration mechanism. previous studies have demonstrated the safety and effectiveness of clearpetra™ in rirs comprehensive comparative investigations between clearpetra™ and traditional uas in rirs are lacking in american population. we aim to compare the outcomes of using va-uas (clearpetra™) or traditional approach (no sheath or non-vacuum-assisted sheath) to treat patients with stone burden between 1.0 - 2.5 cm.

Eligibility criteria:
inclusion criteria: 1. males or females over18 years of age 2. undergoing primary flexible ureteroscopy for retrograde intrarenal surgery 3. total stone burden between 1.0 to 2.5 cm exclusion criteria: 1. undergoing bilateral stone treatment during the same procedure 2. patients with known genitourinary anatomical abnormalities 3. uncorrected coagulopathy 4. patients with urinary diversions 5. chronic external urinary catheters 6. women who are pregnant 7. immunosuppressed patients 8. non-elective procedures

Keywords: nephrolithiasis kidney stone clearpetra ureteral access sheath
influenza vaccine effectiveness in among young children in taiwan

Conditions: Influenza Vaccine Allergy

Summary: this project uses questionnaires to statistically analyze whether influenza vaccination is protective for young children.

this plan is expected to admit 350 children who are admitted to the emergency department or hospitalized due to influenza and are aged from 6 months (inclusive) to under 18 years old. vaccine status, statistical analysis of whether the flu vaccine is protective.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of influenza by flu a+b rapid antigen test * known vaccination status exclusion criteria: * unknown vaccination status

Keywords: influenza vaccine
phase iv trial to determine the safety and immunogenicity of the who formulation of the 2006-2007 fluzone® vaccine

Conditions: Influenza

Summary: to submit remaining available sera to center for biologics evaluation and research (cber) for further analysis by the food and drug administration (fda), the center for disease control and prevention (cdc) and the world health organization (who) to support selection and recommendation of antigen strains for subsequent influenza vaccines.


Eligibility criteria:
inclusion criteria: * participant aged 18 years or older on the day of inclusion. * participant able to attend scheduled visits and to comply with the study procedures during the entire duration of the study. * participant is in reasonably good health as assessed by the investigator. * participant willing and able to meet protocol requirements. * participant willing and able to give informed consent. * for a woman, inability to bear a child or negative serum/urine pregnancy test. exclusion criteria: * self-reported allergy to egg proteins, chicken proteins, or one of the constituents of the vaccine, such as thimerosal or formaldehyde. * an acute illness with or without fever (temperature ≥ 99.5 °f oral) in the 72 hours preceding enrollment in the trial. * clinically significant findings in vital signs (including temperature ≥ 99.5 °f oral) on review of systems. * self-reported history of severe adverse event to any influenza vaccine. * laboratory-confirmed influenza infection or vaccination against influenza in the 6 months preceding enrollment in the study. * any vaccination in the 14 days preceding enrollment in the study or scheduled between visit 1 and visit 3. * vaccination planned in the 4 weeks following fluzone® vaccination at visit 1. * participation in any other interventional drug or vaccine trial within the 30 days preceding or during enrollment into this study. * immunocompromising or immunosuppressive therapy (including systemic steroid use for 2 weeks or more), cancer chemotherapy, or radiation therapy at the time of enrollment, planned during the period of this study, or at any time within the past 6 months. * receipt of blood or blood products within the 3 months preceding enrollment in the study. * diabetes mellitus requiring pharmacological control. * any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with the evaluation of the vaccine. * person deprived of freedom by an administrative or court order (having legal or medical guardian). * for women of childbearing potential, a positive urine pregnancy test, breast feeding, or not using a medically approved form of contraception for the duration of the trial. * current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures. * thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination. * prior personal history of guillain-barré syndrome.

Keywords: influenza influenza vaccine
circulating tumor dna monitoring in platinum-resistant ovarian cancer

Conditions: Ovarian Cancer

Summary: this observational study is conducted to assess the utility of circulating tumor dna in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer，and evaluate the consistency of circulating tumor dna with imaging and ca125 in platinum-resistant ovarian cancer.

the goal of this study is to assess the utility of circulating tumor dna in monitoring the response to pegylated liposomal doxorubicin in platinum-resistant ovarian cancer.this is a single-arm, single-center prospective clinical study. after enrollment, patients will receive standard treatment (pegylated liposomal doxorubicin)and follow-up strategy. peripheral blood samples will be collected from all patients before treatment and 3 weeks after the first cycle of treatment，if necessary, peripheral blood samples also be collected after 2 cycles of treatment.peripheral blood ctdna will be tested for genetic variation based on next-generation sequencing (ngs). finally, this study will to evaluate the consistency of circulating tumor dna with imaging and ca125 in platinum-resistant ovarian cancer.

Eligibility criteria:
inclusion criteria: 1. female, over 18 years of age; 2. patients with histopathological diagnosis of high-grade serous epithelial ovarian cancer; 3. pathological report:phenotype of p53 mutation；or previous genetic tests of tumor tissue indicated tp53 gene mutations; 4. ecog≤ 2; 5. expected survival time ≥3 months; 6. the subjects were able to understand the study process and voluntarily joined the study. exclusion criteria: 1. pregnant and lactating patients; 2. patients with severe or uncontrolled infections; 3. patients who are allergic or intolerant to the investigational drug; 4. patients who are enrolled in or within a month of another clinical trial.

Keywords: ctdna pegylated liposomal doxorubicin ovarian cancer